Nanjing Vazyme Biotech Co Ltd
SSE:688105
Income Statement
Earnings Waterfall
Nanjing Vazyme Biotech Co Ltd
Revenue
|
2.1B
CNY
|
Cost of Revenue
|
-749.5m
CNY
|
Gross Profit
|
1.4B
CNY
|
Operating Expenses
|
-1.7B
CNY
|
Operating Income
|
-316.5m
CNY
|
Other Expenses
|
84.6m
CNY
|
Net Income
|
-231.9m
CNY
|
Income Statement
Nanjing Vazyme Biotech Co Ltd
Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||
Revenue |
2 390
N/A
|
1 715
-28%
|
1 869
+9%
|
2 302
+23%
|
2 663
+16%
|
2 885
+8%
|
3 569
+24%
|
2 896
-19%
|
2 520
-13%
|
2 133
-15%
|
|
Gross Profit | |||||||||||
Cost of Revenue |
(257)
|
(224)
|
(390)
|
(564)
|
(671)
|
(817)
|
(1 393)
|
(976)
|
(865)
|
(750)
|
|
Gross Profit |
2 133
N/A
|
1 491
-30%
|
1 479
-1%
|
1 738
+18%
|
1 992
+15%
|
2 068
+4%
|
2 176
+5%
|
1 920
-12%
|
1 656
-14%
|
1 384
-16%
|
|
Operating Income | |||||||||||
Operating Expenses |
(733)
|
(641)
|
(734)
|
(891)
|
(1 022)
|
(1 158)
|
(1 345)
|
(1 874)
|
(1 849)
|
(1 700)
|
|
Selling, General & Administrative |
(467)
|
(422)
|
(502)
|
(588)
|
(665)
|
(731)
|
(912)
|
(920)
|
(905)
|
(845)
|
|
Research & Development |
(210)
|
(188)
|
(220)
|
(263)
|
(303)
|
(352)
|
(380)
|
(410)
|
(411)
|
(373)
|
|
Depreciation & Amortization |
0
|
0
|
(27)
|
0
|
0
|
0
|
(37)
|
0
|
0
|
0
|
|
Other Operating Expenses |
(56)
|
(30)
|
15
|
(39)
|
(54)
|
(75)
|
(16)
|
(545)
|
(532)
|
(483)
|
|
Operating Income |
1 400
N/A
|
850
-39%
|
744
-12%
|
847
+14%
|
969
+14%
|
910
-6%
|
832
-9%
|
46
-94%
|
(193)
N/A
|
(317)
-64%
|
|
Pre-Tax Income | |||||||||||
Interest Income Expense |
21
|
23
|
27
|
37
|
57
|
81
|
90
|
100
|
100
|
85
|
|
Non-Reccuring Items |
0
|
(0)
|
0
|
0
|
(0)
|
1
|
(204)
|
(0)
|
0
|
5
|
|
Gain/Loss on Disposition of Assets |
0
|
0
|
(2)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
|
Total Other Income |
(14)
|
(5)
|
(4)
|
(6)
|
(6)
|
(4)
|
(107)
|
(109)
|
(108)
|
(119)
|
|
Pre-Tax Income |
1 407
N/A
|
868
-38%
|
764
-12%
|
878
+15%
|
1 020
+16%
|
987
-3%
|
609
-38%
|
36
-94%
|
(201)
N/A
|
(345)
-72%
|
|
Net Income | |||||||||||
Tax Provision |
(193)
|
(101)
|
(86)
|
(105)
|
(119)
|
(110)
|
(16)
|
75
|
98
|
112
|
|
Income from Continuing Operations |
1 214
|
767
|
678
|
773
|
900
|
878
|
594
|
111
|
(102)
|
(234)
|
|
Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
|
Net Income (Common) |
1 214
N/A
|
767
-37%
|
678
-12%
|
773
+14%
|
900
+16%
|
878
-3%
|
594
-32%
|
112
-81%
|
(101)
N/A
|
(232)
-130%
|
|
EPS (Diluted) |
3.03
N/A
|
1.92
-37%
|
1.87
-3%
|
1.93
+3%
|
2.25
+17%
|
2.19
-3%
|
1.49
-32%
|
0.28
-81%
|
-0.25
N/A
|
-0.58
-132%
|